Guggenheim Initiates Coverage On MapLight Therapeutics with Neutral Rating

Benzinga Newsdesk www.benzinga.com Neutral 83.9%

Neg 0% Neu 83.9% Pos 0%

Guggenheim analyst Delma Caiati initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Neutral rating.

Comments

No comments yet. Be the first!